Rtw Investments Reduces $45M in Stryker Corporation ($SYK)
RTW Investments cut its stake in Stryker by 59%, retaining 100,000 shares.
Key Points
- RTW Investments cut its stake in Stryker Corporation by 59%, reducing its holdings by 145,000 shares to 100,000 shares, valued at $30.56 million.
- Stryker shares traded at $305.64, with a market cap of $119.69 billion and a P/E ratio of 36.09.
- Insider activity included several sales, and analysts maintained a 'buy' consensus with a target mean price of $386.80.
RTW Investments recently reduced its stake in Stryker Corporation (NYSE:SYK) by 59%. According to its latest Form 13F filing with the SEC, the fund sold 145,000 shares during the reporting period, bringing its total holdings down to 100,000 shares. The position is now valued at approximately $30.56 million.
What Changed in RTW Investments' Stryker Position
RTW Investments decreased its holdings in Stryker Corporation by 145,000 shares, which is a 59% reduction. Before the move, the fund held 245,000 shares. Following the sale, RTW now retains 100,000 shares valued at about $30.56 million. This significant reduction suggests a strategic shift in RTW's investment approach to Stryker.
Other Institutional Activity in Stryker
In the same period, other major investors also adjusted their positions in Stryker. BlackRock, Inc. increased its holdings by 152,722 shares, ending with 27,602,049 shares worth approximately $9.07 billion. Vanguard Capital Management LLC held steady with 22,383,181 shares valued at about $7.35 billion. Meanwhile, Greenleaf Trust reduced its position by 626,139 shares, holding 15,938,070 shares worth $5.24 billion. JPMorgan Chase & Co significantly boosted its stake by 3,451,783 shares, bringing its total to 15,596,897 shares valued at $5.09 billion.
Stryker Stock Snapshot
Shares of Stryker Corporation (NYSE:SYK) recently traded around $305.64. The company has a market capitalization of $119.69 billion and a P/E ratio of 36.09. Its forward P/E is 18.67, indicating expectations of future earnings growth. With a beta of 0.785, Stryker's stock is less volatile than the market. The stock's 52-week range is between $281.00 and $404.87. It has a 50-day moving average of $315.17 and a 200-day moving average of $352.36.
Recent Earnings
Stryker reported revenue of $25.27 billion with a revenue growth rate of 2.6%. The company showed a net margin of 13.21% and return on equity of 15.2%. Earnings per share (EPS) stood at $8.65. The next earnings report is expected on April 30, 2026.
Dividend
Stryker offers an annual dividend rate of $3.52, with a yield of 1.13%. The dividend payout ratio is 39.81%, indicating a balanced approach to returning earnings to shareholders.
Insider Buying and Selling at Stryker Corporation
Several insiders at Stryker Corporation have been active recently. On June 1, 2026, Spencer Stiles, President and COO, sold 1,607 shares. Robert Fletcher, VP and Chief Legal Officer, sold 4,544 shares on May 28, 2026, at an average price of $306.87 under a planned sale. Ronda Stryker sold 310,000 shares on May 26, 2026, at $312.23. Additionally, Kathryn Fink, VP and Chief HR Officer, sold 8,720 shares on May 11, 2026, at $283.69, alongside other transactions earlier in May.
Analysts Set New Price Targets
Analysts have maintained a positive outlook on Stryker. On June 5, 2026, Leerink Partners maintained a 'buy' rating with a $407.00 target. Truist Securities reiterated a 'hold' rating with a $330.00 target on May 4, 2026. Barclays, Canaccord Genuity, JP Morgan, Evercore ISI Group, Wells Fargo, and Needham all maintained 'buy' ratings with targets ranging from $355.00 to $418.00 in early May. The consensus rating remains 'buy', with an average target price of $386.80 based on 25 analyst opinions.
About Stryker Corporation
Stryker Corporation, headquartered in Portage, Michigan, is a leading medical technology company. It operates through two main segments: MedSurg and Neurotechnology, and Orthopaedics. The company provides a wide range of products including surgical equipment, patient safety technologies, and implants for joint replacements. With a workforce of 56,000 employees, Stryker serves healthcare professionals worldwide, selling its products in approximately 61 countries.
Bottom Line
RTW Investments' decision to cut its stake in Stryker by 59% reflects a notable shift in its investment strategy. Investors watch such moves closely as part of their broader analysis. It's important to remember that 13F filings are backward-looking and may not reflect current positions. Stryker remains a key player in the medical devices sector, with strong institutional backing and a positive analyst outlook.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.